DEA Controlled Substance Importer Registration Application: Usona Institute
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
Usona Institute, a nonprofit medical research organization based in Wisconsin, has submitted an application to the U.S. Drug Enforcement Administration (DEA) to be registered as an importer of one or more basic classes of controlled substances. This registration is required under the Controlled Substances Act (CSA) for any entity seeking to legally import scheduled drugs into the United States. Usona Institute is known for its clinical research into psilocybin and other psychedelic compounds as potential therapies for mental health conditions such as major depressive disorder. The registration application likely pertains to Schedule I or Schedule II substances needed for ongoing or planned clinical trials. The DEA publishes such notices in the Federal Register to provide public transparency and allow interested parties to comment or object to the application within a designated period. The granting of this registration would authorize Usona to import controlled substances strictly for research purposes under DEA oversight.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Usona Institute has formally applied to the DEA for importer registration status under the Controlled Substances Act as of March 30, 2026
- Application covers importation of basic class(es) of controlled substances, likely Schedule I or II psychedelic compounds (e.g., psilocybin)
- Public notice published in the Federal Register to allow third-party comments or objections within the statutory comment period
+ 2 more changes with Pro
Obligations
What this law requires
Obtain DEA importer registration before importing any controlled substances into the United States
Limit imported controlled substances strictly to research purposes as authorized by DEA registration
Operate under DEA oversight and comply with all Controlled Substances Act requirements
Disclose specific basic classes of controlled substances being imported in the registration application
Allow public comment and objection period for the DEA registration application as published in the Federal Register